Home > Maligne hematologie > Myeloïde ziekten > Myeloproliferatieve aandoeningen > Essentiele trombocytose (ET) > MK3543-006 ET

MK3543-006 ET

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants with Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea. https://clinicaltrials.gov/study/NCT06079879?term=mk3543&rank=6

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 20-6-2025, 2:29